Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADR005
MIFTS: 59

Adrenal Carcinoma

Categories: Rare diseases, Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adrenal Carcinoma

About this section

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 12 37 15
Adrenal Cancer 12 76 53 55 73
Adrenal Gland Cancer 12 43 15
Adrenal Gland Neoplasms 44 73
Malignant Neoplasm of Adrenal Gland 12
Carcinoma of the Adrenal Gland 12
Neoplasm of the Adrenal Gland 29
Tumor of the Adrenal Gland 12
Neoplasm of Adrenal Gland 12
Adrenocortical Carcinoma 73
Malignant Adrenal Tumor 12
Adrenal Neoplasm 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3950 DOID:3953
ICD10 33 C74 C74.9
ICD9CM 35 194.0
MeSH 44 D000310
NCIt 50 C2859 C9338
KEGG 37 H00033
Sources

Summaries for Adrenal Carcinoma

About this section
NIH Rare Diseases : 53 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). There are three different types of adrenal cancer which vary by location and the age at which they are often diagnosed:Adrenocortical carcinoma - The most common type of adrenal cancer which develops in the adrenal cortex (the outer part of the adrenal gland) Neuroblastoma - A childhood cancer that begins in the adrenal medulla (the inner part of the adrenal gland) Pheochromocytoma - A neuroendocrine tumor that begins in the adrenal medulla The signs and symptoms associated with the condition largely depend on if the cancer is 'functioning' (producing hormones) or 'nonfunctioning' (not producing hormones) and which hormones are present in excess. In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer. Treatment may include a combination of surgery, hormone therapy, chemotherapy and radiation therapy.

MalaCards based summary : Adrenal Carcinoma, also known as adrenal cancer, is related to adrenal gland hyperfunction and pheochromocytoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Aldosterone synthesis and secretion. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include the adrenal gl, adrenal gland and kidney, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

MedlinePlus : 43 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

Wikipedia : 76 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Sources

Related Diseases for Adrenal Carcinoma

About this section

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 adrenal gland hyperfunction 30.4 CRH CYP21A2 POMC
2 pheochromocytoma 29.7 CRH ENO2 POMC SYP
3 hypoaldosteronism 29.0 CYP11B2 POMC REN
4 conn's syndrome 26.5 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
5 lipoid congenital adrenal hyperplasia 24.5 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR5A1
6 adrenocortical carcinoma, hereditary 23.2 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 IGF2
7 adrenal neuroblastoma 11.0
8 adrenal medulla cancer 11.0
9 ureter small cell carcinoma 10.9 ENO2 SYP
10 gangliocytoma 10.9 CRH SYP
11 malignant sertoli cell tumor 10.9 ENO2 SYP
12 urinary bladder small cell neuroendocrine carcinoma 10.9 ENO2 SYP
13 auditory system cancer 10.9 ENO2 SYP
14 sinonasal undifferentiated carcinoma 10.9 ENO2 SYP
15 sensory organ benign neoplasm 10.9 ENO2 SYP
16 gallbladder small cell carcinoma 10.9 ENO2 SYP
17 pancreatic somatostatinoma 10.9 ENO2 SYP
18 cutaneous ganglioneuroma 10.9 ENO2 SYP
19 extrahepatic bile duct adenocarcinoma 10.9 ENO2 SYP
20 small cell carcinoma of the bladder 10.9 ENO2 SYP
21 papillary tumor of the pineal region 10.9 ENO2 SYP
22 orbital cancer 10.9 ENO2 SYP
23 middle ear adenoma 10.8 ENO2 SYP
24 ovarian carcinosarcoma 10.8 ENO2 SYP
25 pulmonary large cell neuroendocrine carcinoma 10.8 ENO2 SYP
26 atypical follicular adenoma 10.8 ENO2 SYP
27 central nervous system primitive neuroectodermal neoplasm 10.8 ENO2 SYP
28 cerebellum cancer 10.8 ENO2 SYP
29 subependymal glioma 10.8 ENO2 SYP
30 olfactory nerve neoplasm 10.8 ENO2 SYP
31 hypothalamic disease 10.8 CRH POMC
32 cauda equina neoplasm 10.8 ENO2 SYP
33 lymphocytic hypophysitis 10.8 ENO2 POMC
34 extraosseous chondrosarcoma 10.8 ENO2 SYP
35 gastric leiomyosarcoma 10.8 ENO2 IGF2
36 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.8 CYP21A2 POMC
37 benign ependymoma 10.8 ENO2 SYP
38 malignant teratoma 10.8 ENO2 SYP
39 transsexualism 10.8 CYP17A1 CYP21A2
40 pituitary carcinoma 10.8 CRH POMC
41 astroblastoma 10.8 ENO2 SYP
42 cerebral ventricle cancer 10.7 ENO2 SYP
43 cerebrum cancer 10.7 ENO2 SYP
44 sella turcica neoplasm 10.7 POMC SYP
45 pineal gland cancer 10.7 ENO2 SYP
46 acth deficiency, isolated 10.7 CRH POMC
47 endometrial small cell carcinoma 10.7 ENO2 SYP
48 melanotic neuroectodermal tumor 10.7 ENO2 SYP
49 tuberculum sellae meningioma 10.7 POMC SYP
50 nodular ganglioneuroblastoma 10.7 ENO2 SYP

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma
Sources

Symptoms & Phenotypes for Adrenal Carcinoma

About this section

UMLS symptoms related to Adrenal Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CYP21A2 IGF2 LIAS NR0B1 POMC STAR

MGI Mouse Phenotypes related to Adrenal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 SYP POMC REN ENO2 CRH GRN
2 growth/size/body region MP:0005378 10.1 STAR REN CRH CYP11A1 IGF2 CYP11B1
3 homeostasis/metabolism MP:0005376 10.07 STAR REN GRN CYP11A1 IGF2 CYP11B1
4 endocrine/exocrine gland MP:0005379 10.02 STAR POMC CRH CYP11A1 IGF2 CYP11B1
5 nervous system MP:0003631 9.9 SYP POMC REN ENO2 CRH GRN
6 renal/urinary system MP:0005367 9.5 REN POMC CRH IGF2 CYP11B1 CYP11B2
7 reproductive system MP:0005389 9.28 REN STAR GRN CYP11A1 IGF2 NR0B1
Sources

Drugs & Therapeutics for Adrenal Carcinoma

About this section

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
2
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Mitotane Approved Phase 3,Phase 2,Not Applicable 53-19-0 4211
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-23-7 5754
11
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
12
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 36339 667484
13
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
18 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
19 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 insulin Phase 3,Phase 2
21 Insulin, Globin Zinc Phase 3,Phase 2
22 Mitogens Phase 3,Phase 2
23 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
26 Etoposide phosphate Phase 3,Phase 2
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
29 Adjuvants, Anesthesia Phase 3
30 Analgesics Phase 3
31 Analgesics, Opioid Phase 3
32 Anesthetics Phase 3,Phase 1,Phase 2
33 Anesthetics, General Phase 3,Phase 1,Phase 2
34 Anesthetics, Intravenous Phase 3,Phase 1,Phase 2
35 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
36 Narcotics Phase 3
37 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Adrenocorticotropic Hormone Phase 3,Phase 2
39 beta-endorphin Phase 3
40 Contraceptive Agents Phase 3,Phase 2
41 Contraceptives, Oral Phase 3
42 Contraceptives, Postcoital Phase 3
43 Cortisol succinate Phase 3,Phase 2,Not Applicable
44 Hormone Antagonists Phase 3,Phase 2,Not Applicable
45 Hormones Phase 3,Phase 2,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Not Applicable
47 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2,Not Applicable
48 Hydrocortisone acetate Phase 3,Phase 2,Not Applicable
49 Luteolytic Agents Phase 3
50 Melanocyte-Stimulating Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
8 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
9 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
10 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Not yet recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
11 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
12 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
17 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
18 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
19 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
20 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
21 A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
22 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
23 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherinâ„¢)
24 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
25 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
26 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
27 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
28 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
29 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
30 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
31 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
32 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
33 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
34 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
35 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
36 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
37 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
38 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Active, not recruiting NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
39 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Active, not recruiting NCT02804750 Phase 2 CORT125134
40 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
41 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
42 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
43 Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
44 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
45 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
46 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
47 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
48 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
49 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
50 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Sources

Genetic Tests for Adrenal Carcinoma

About this section

Genetic tests related to Adrenal Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of the Adrenal Gland 29
Sources

Anatomical Context for Adrenal Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Carcinoma:

19
The Adrenal Gl

MalaCards organs/tissues related to Adrenal Carcinoma:

41
Adrenal Gland, Kidney, Cortex, Adrenal Cortex, Testes, Lung, Liver
Sources

Publications for Adrenal Carcinoma

About this section

Articles related to Adrenal Carcinoma:

(show top 50) (show all 180)
# Title Authors Year
1
Cushing syndrome due to adrenal carcinoma. ( 29633121 )
2018
2
Aggressive adrenal carcinoma in a young patient with Multiple Endocrine Neoplasia 1 syndrome. ( 28625514 )
2017
3
Surgical treatment of adrenal carcinoma. ( 28754418 )
2017
4
Mixed corticomedullary adrenal carcinoma - case report: Comparison in features, treatment and prognosis with the other two reported cases. ( 28199934 )
2017
5
Adrenohepatic fusion: Adhesion or invasion in primary virilizant giant adrenal carcinoma? Implications for surgical resection. Two case report and review of the literature. ( 26684865 )
2016
6
Sarcomatoid Adrenal Carcinoma: Case Report with Contribution to Pathogenesis. ( 27688079 )
2016
7
Evaluation of a large adrenal carcinoma withA 3D reconstruction of computed tomography images: A case report andA literature review. ( 27567750 )
2016
8
Rare cardiac involvement in adrenal carcinoma. ( 26301653 )
2015
9
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. ( 25497672 )
2015
10
A Rare Presentation of Primary Hyperparathyroidism with Concurrent Aldosterone-Producing Adrenal Carcinoma. ( 26161274 )
2015
11
Pathology in practice. Mediastinal thyroid follicular carcinoma and adrenal carcinoma. ( 25587729 )
2015
12
Functional ectopic adrenal carcinoma in a dog. ( 25183891 )
2014
13
Incidental renal cell carcinoma originating from a native kidney after en-bloc resection for adrenal carcinoma in a kidney transplant recipient. ( 24656033 )
2014
14
Histoplasmosis mimicking adrenal carcinoma. ( 24600775 )
2014
15
Senile primary aldosteronism associated with adrenal carcinoma. ( 24796641 )
2014
16
Adrenal carcinoma: a retrospective analysis of our series. ( 23540614 )
2013
17
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( 23275528 )
2013
18
A case of androgen-secreting adrenal carcinoma with non-classical congenital adrenal hyperplasia. ( 24251173 )
2013
19
Neoadjuvant chemotherapy and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava thrombus: case report and literature review. ( 23810165 )
2013
20
Mixed corticomedullary adrenal carcinoma. ( 23435808 )
2013
21
Giant adrenal carcinoma associated with renal vein and inferior vena cava thrombus. Case report and literature review. ( 22732784 )
2012
22
The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. ( 22488095 )
2012
23
Feminizing adrenal carcinoma presenting with heart failure and ventricular tachycardia. ( 22937299 )
2012
24
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. ( 22096502 )
2011
25
Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells. ( 21529220 )
2011
26
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. ( 20106872 )
2010
27
Primary hepatocellular carcinoma in ectopic liver masquerading as left adrenal carcinoma: a rare occurrence. ( 21139837 )
2010
28
Seladin-1 expression is regulated by promoter methylation in adrenal cancer. ( 20465827 )
2010
29
Virilizing adrenal carcinoma in a 3-year-old boy: A rarity. ( 20931019 )
2010
30
(-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. ( 19414399 )
2009
31
Virilizing adrenal carcinoma with inferior vena cava thrombus. ( 19574684 )
2009
32
A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis. ( 19578356 )
2009
33
Cushing syndrome and adrenal carcinoma: a clinical case. ( 19537129 )
2009
34
Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. ( 18491247 )
2008
35
A young woman with a severe bilateral pneumonia as the presenting sign of an adrenal carcinoma. ( 18349468 )
2008
36
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. ( 18505909 )
2008
37
High dose 17 beta-estradiol and the alpha-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the beta-estrogen agonist DPN does not. ( 18491249 )
2008
38
Estrogen and progesterone lower cyclin B1 AND D1 expression, block cell cycle in G2/M, and trigger apoptosis in human adrenal carcinoma cell cultures. ( 18491248 )
2008
39
Pulmonary Infarction: A rare case of adrenal carcinoma. ( 21654947 )
2007
40
A case of polymyositis associated with adrenal carcinoma. ( 17880299 )
2007
41
Adrenal carcinoma. ( 21614222 )
2006
42
Unusual visualization of an adrenal carcinoma on NP-59 scintiscan. ( 16618615 )
2006
43
Laparoscopic adrenalectomy for adrenal carcinoma and metastases. ( 16479203 )
2006
44
Surgical complications after resection of adrenal carcinoma. ( 17167987 )
2006
45
An accessory spleen mimics a left adrenal carcinoma. ( 16369388 )
2005
46
Prenatal diagnosis of fetal bilateral adrenal carcinoma. ( 16254889 )
2005
47
Thoracoscopic transdiaphragmatic adrenalectomy for isolated locally recurrent adrenal carcinoma. ( 16409610 )
2005
48
Cushing's syndrome due to adrenal carcinoma. ( 15937531 )
2005
49
Extracts from two marine sponges lower cyclin B1 levels, cause a G2/M cell cycle block and trigger apoptosis in SW-13 human adrenal carcinoma cells. ( 15284019 )
2004
50
Cytotoxic T-cell response against steroidogenic acute regulatory protein using DNA vaccination followed by vaccinia virus infection in a mouse adrenal carcinoma model. ( 15241733 )
2004
Sources

Variations for Adrenal Carcinoma

About this section

Cosmic variations for Adrenal Carcinoma:

9
(show top 50) (show all 65)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.593T>C p.L198P 3:10149916-10149916 29
2 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.499C>T p.R167W 3:10149822-10149822 29
3 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.250G>A p.V84M 3:10142097-10142097 29
4 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.4558C>T p.Q1520* 17:31260496-31260496 29
5 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.3721C>T p.R1241* 17:31235623-31235623 29
6 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 27
7 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 27
8 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 27
9 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 27
10 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 27
11 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 27
12 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 27
13 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 27
14 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 27
15 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 27
16 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 27
17 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 27
18 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 27
19 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 27
20 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 27
21 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 27
22 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 27
23 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 27
24 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 27
25 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 27
26 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 27
27 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 27
28 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 27
29 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69fs*7 17:31159009-31159009 27
30 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 27
31 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 27
32 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 27
33 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 27
34 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 27
35 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.37G>C p.G13R 11:534286-534286 27
36 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,benign c.103G>T p.G35W 1:226064454-226064454 27
37 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1638C>A p.N546K 8:38417331-38417331 27
38 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1592C>T p.P531L 2:46380264-46380264 27
39 COSM6196778 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1104G>A p.M368I 2:46376608-46376608 27
40 COSM6196613 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1589C>A p.A530E 2:46380261-46380261 27
41 COSM6188649 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1595A>G p.Y532C 2:46380267-46380267 27
42 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 22
43 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 22
44 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 22
45 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 22
46 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 22
47 COSM27887 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>T p.R201C 20:58909365-58909365 22
48 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 22
49 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 22
50 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 22
Sources

Expression for Adrenal Carcinoma

About this section
Search GEO for disease gene expression data for Adrenal Carcinoma.
Sources

Pathways for Adrenal Carcinoma

About this section

Pathways related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytochrome P450 - arranged by substrate type 66
Show member pathways
 12.91 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
2
Aldosterone synthesis and secretion 37
Show member pathways
 12.67 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3
Glucose / Energy Metabolism 4
12.25 CYP11A1 CYP17A1 ENO2 STAR
4
Steroid hormone biosynthesis 37
Show member pathways
 11.47 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
5
Corticotropin-releasing hormone signaling pathway 1
11.4 CRH CYP11A1 CYP11B1 CYP21A2 POMC STAR
6
Ovarian steroidogenesis 37
11.23 CYP11A1 CYP17A1 STAR
7
Metabolism of steroid hormones 66
Show member pathways
 11.11 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
8
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.94 CYP11B1 CYP11B2 CYP17A1 CYP21A2
9
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.25 CRH POMC
Sources

GO Terms for Adrenal Carcinoma

About this section

Cellular components related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.92 CRH CYP17A1 ENO2 STAR

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 CCNB1 CRH REN STAR
2 male gonad development GO:0008584 9.85 NR0B1 NR5A1 REN STAR
3 cholesterol metabolic process GO:0008203 9.83 CYP11A1 CYP11B1 CYP11B2 STAR
4 glucose homeostasis GO:0042593 9.81 CYP11B1 IGF2 POMC
5 response to organic substance GO:0010033 9.8 IGF2 REN STAR
6 steroid metabolic process GO:0008202 9.8 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
7 regulation of blood pressure GO:0008217 9.78 CYP11B1 POMC REN
8 response to immobilization stress GO:0035902 9.71 CRH NR0B1 REN
9 cellular response to peptide hormone stimulus GO:0071375 9.69 CYP11A1 CYP11B1 CYP11B2
10 adrenal gland development GO:0030325 9.67 CRH NR0B1 NR5A1
11 small molecule metabolic process GO:0044281 9.65 CYP11A1 CYP11B1 CYP11B2
12 regulation of neuronal synaptic plasticity GO:0048168 9.64 STAR SYP
13 response to corticosterone GO:0051412 9.63 CRH STAR
14 secondary metabolite biosynthetic process GO:0044550 9.63 CYP11A1 CYP11B1 CYP11B2
15 hypothalamus development GO:0021854 9.62 CRH NR0B1
16 cellular response to potassium ion GO:0035865 9.61 CYP11B1 CYP11B2
17 dehydroaustinol biosynthetic process GO:1900563 9.61 CYP11A1 CYP11B1 CYP11B2
18 regulation of steroid biosynthetic process GO:0050810 9.6 NR5A1 STAR
19 sex determination GO:0007530 9.59 NR0B1 NR5A1
20 diterpenoid metabolic process GO:0016101 9.58 CRH STAR
21 mineralocorticoid biosynthetic process GO:0006705 9.58 CYP11B2 CYP21A2
22 cortisol metabolic process GO:0034650 9.58 CYP11A1 CYP11B1 CYP11B2
23 aldosterone biosynthetic process GO:0032342 9.57 CYP11B1 CYP11B2
24 cortisol biosynthetic process GO:0034651 9.56 CYP11B1 CYP11B2
25 C21-steroid hormone biosynthetic process GO:0006700 9.56 CYP11A1 CYP11B1 CYP11B2 STAR
26 sterol metabolic process GO:0016125 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
27 austinol biosynthetic process GO:1900560 9.54 CYP11A1 CYP11B1 CYP11B2
28 steroid biosynthetic process GO:0006694 9.5 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR0B1
29 glucocorticoid biosynthetic process GO:0006704 9.1 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
30 oxidation-reduction process GO:0055114 10.04 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.8 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
2 hormone activity GO:0005179 9.61 CRH IGF2 POMC
3 iron ion binding GO:0005506 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 insulin-like growth factor receptor binding GO:0005159 9.46 IGF2 REN
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.43 CYP11A1 CYP11B1 CYP11B2
6 corticosterone 18-monooxygenase activity GO:0047783 9.37 CYP11B1 CYP11B2
7 heme binding GO:0020037 9.35 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
8 steroid 11-beta-monooxygenase activity GO:0004507 9.32 CYP11B1 CYP11B2
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.02 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
Sources

Sources for Adrenal Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....